Genetic modifications boost chrexanthomycin yield and neuroprotective potential.

Area of Science:

• Natural Product Biosynthesis
• Neuropharmacology

Background:

• Chrexanthomycins are pentangular polyphenols with demonstrated neuroprotective properties.
• Low yields of chrexanthomycins limit their therapeutic applications.

Purpose of the Study:

• Elucidate the biosynthetic pathway of chrexanthomycins.
• Enhance large-scale production of chrexanthomycins.
• Discover novel derivatives with improved neuroprotective activities.

Main Methods:

• Heterologous expression of the chr gene cluster.
• Genetic manipulation of regulatory genes (knockout/overexpression).
• In vitro biochemical assays and enzyme function exploration (ChrN, UGT50).
• Neuroprotection evaluation in Caenorhabditis elegans models.

Main Results:

• The biosynthetic pathway of chrexanthomycins was elucidated.
• Yields were increased over 10-fold in engineered Streptomyces chrestomyceticus.
• Chrexanthomycin G, a novel derivative, was identified with significant neuroprotective activity.
• Chrexanthomycin G alleviates amyloid-beta induced oxidative stress, inhibits aggregation, and improves memory in C. elegans.

Conclusions:

• The study provides critical insights into chrexanthomycin biosynthesis and neuroprotective mechanisms.
• Findings establish a foundation for developing chrexanthomycins as therapeutics for neurodegenerative diseases.